Developer docs
API playgroundTry for free, no card

Search company profiles

Prism AI

Full company profile

uuid0006w78

Namestring
Prism AI
Legal namestring
PRISM AI PTE. LTD.
Websiteurl
prism-ai.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Prism AI is a University of Utah spinoff founded in 2024 and headquartered in Salt Lake City, building what it describes as an operating system for drug development and biomarker discovery. Its core technology is a quantum mechanics-based AI/ML approach using multitensor comparative spectral decompositions to analyze millions to billions of molecular features (tumor DNA, blood DNA, tumor RNA) from patient cohorts as small as 20-100 individuals, a regime where conventional AI is reported to underperform due to data scarcity. The company has validated the method against a neuroblastoma cohort of 101 patients across approximately 6 million features, discovering new predictors of patient life expectancy that it claims consistently outperform standard biomarkers and replicate across hospitals. Therapeutic targets identified by the AI are experimentally validated using CRISPR-Cas9 gene editing.

The portfolio also extends beyond therapeutics. Under the Prism AI Therapeutics sub-brand, the company addresses biotech and pharmaceutical customers seeking to optimize clinical trial design and drug target identification. Separately, a Singapore-incorporated entity (PRISM AI PTE. LTD.) launched PYRA, a multi-agent coordination system with a Credit System and reputation-based distribution model, in March 2026, and additional Developer Analytic Tools automate insight extraction from session replays. Leadership comprises CEO Asaf Zviran, Chief Science Officer Orly Alter, and CTO Daniel Shabtai. Business model mechanics are not publicly disclosed: pricing is not published, no revenue figure is available, no paying customers are named, and the only funding entry records $0 from Evolution VC Partners and Vela Partners in early 2025.

Short descriptiontext

Prism AI is a University of Utah spinoff applying a proprietary quantum mechanics-based AI technique to genomic and molecular data, enabling biotech and pharma customers to optimize clinical trial design, identify drug targets, and predict cancer outcomes from small patient cohorts.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSalt Lake City, United States
HQ citystring
Salt Lake City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
AI drug discovery, biomarker analysis, multi-agent systems, quantum AI, molecular profiling
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHDAEANAA
End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise
SECONDARYBPAEAHAK
Industry/Domain Analytics Solutions & Accelerators
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery
Social media profiles1 record
Cost components2 values
Technology or R&D, Personnel
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1PYRA
Description

A multi-agent system designed to coordinate AI agents through a unified execution network where users submit objectives and the platform routes tasks across multiple agents to produce combined outputs. Includes an economic layer featuring a Credit System and reputation-based distribution model.

einpresswire.com
Core offering1 text field

Prism AI develops quantum mechanics-based AI/ML algorithms that analyze millions to billions of molecular features from small patient cohorts (20-100 people) to predict cancer treatment outcomes and identify optimal drug targets. The company offers Prism AI Therapeutics for biotech and pharma clinical trial optimization, PYRA—a multi-agent system that coordinates AI agents through a unified execution network—and developer analytic tools that automate insight extraction from session replays.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Discovered two new predictors of neuroblastoma patient life expectancy that consistently outperform standard biomarkers
+2 more records
Product overview1 text field

Prism AI operates as a multi-product technology company with distinct offerings across different domains. The portfolio includes Prism AI Therapeutics (a healthcare/biotech spinoff using quantum AI for cancer research), PYRA (a multi-agent coordination system for AI execution), and Developer Analytic Tools (session replay analytics for product teams). These products address different market segments including biotech/pharmaceutical research, AI agent orchestration, and developer productivity tools.

Product and service3 records
1Prism AI Therapeutics
CategoryAI Drug Discovery / Computational Biology
Description

A University of Utah spinoff commercializing quantum AI algorithms for biotech and pharmaceutical companies to identify optimal patient subgroups and drug targets for clinical trials, validated through CRISPR-Cas9 gene editing.

2PYRA
CategoryMulti-Agent AI Orchestration
Description

A multi-agent system designed to coordinate AI agents through a unified execution network where users submit objectives and the platform routes tasks across multiple agents to produce combined outputs, featuring an economic layer with a Credit System and reputation-based distribution model.

3Developer Analytic Tools
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI for clinical and translational research using patient-level data to discover biomarkers and predict treatment outcomes — the closest peer to Prism's biomarker and subgroup discovery from patient cohort data.

TypeDirect peer
Description

Machine-learning-enabled drug discovery company combining wet-lab biology with predictive models to identify targets and patient subgroups — closely aligned with Prism's small-cohort, biology-grounded AI approach.

TypeDirect peer
Description

AI platform for drug discovery and biomarker identification using biomedical knowledge graphs and ML — comparable AI-for-discovery and target-identification value proposition.

TypeDirect peer
Description

Causal AI platform for patient-level outcome prediction and biomarker discovery from real-world and clinical data — closely aligned with Prism's predictive modeling from small patient cohorts.

TypeDirect peer
Description

AI platform for pathology-based biomarker discovery and diagnostic development — comparable on AI-driven biomarker identification supporting pharma clinical programs.

TypeBroad incumbent
Description

AI solutions for clinical and real-world evidence analytics serving pharma R&D and commercialization — overlapping incumbent serving the same biotech/pharma buyer with adjacent analytics offerings.

7Tempus Labs
TypeBroad incumbent
Description

Large AI-enabled precision medicine company aggregating clinical and molecular data for oncology — broader incumbent that overlaps with Prism's biomarker and patient-stratification use cases for pharma/biotech customers.

TypeDirect peer
Description

AI-driven precision medicine and drug discovery company using machine learning to design therapeutics and stratify patients — comparable end-to-end platform positioning to Prism AI Therapeutics.

TypeDirect peer
Description

Physics-based and AI-driven molecular simulation platform for drug discovery and materials — comparable on computationally intensive molecular modeling feeding pharma R&D workflows.

TypeDirect peer
Description

AI-driven drug discovery platform using high-throughput biology and machine learning to identify therapeutics — directly comparable to Prism AI Therapeutics on AI-for-drug-development positioning.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prism AI

AI Drug Discoveryprism-ai.com

Prism AI is a University of Utah spinoff applying a proprietary quantum mechanics-based AI technique to genomic and molecular data, enabling biotech and pharma customers to optimize clinical trial design, identify drug targets, and predict cancer outcomes from small patient cohorts.

What Prism AI does

Prism AI is a University of Utah spinoff founded in 2024 and headquartered in Salt Lake City, building what it describes as an operating system for drug development and biomarker discovery. Its core technology is a quantum mechanics-based AI/ML approach using multitensor comparative spectral decompositions to analyze millions to billions of molecular features (tumor DNA, blood DNA, tumor RNA) from patient cohorts as small as 20-100 individuals, a regime where conventional AI is reported to underperform due to data scarcity. The company has validated the method against a neuroblastoma cohort of 101 patients across approximately 6 million features, discovering new predictors of patient life expectancy that it claims consistently outperform standard biomarkers and replicate across hospitals. Therapeutic targets identified by the AI are experimentally validated using CRISPR-Cas9 gene editing.

The portfolio also extends beyond therapeutics. Under the Prism AI Therapeutics sub-brand, the company addresses biotech and pharmaceutical customers seeking to optimize clinical trial design and drug target identification. Separately, a Singapore-incorporated entity (PRISM AI PTE. LTD.) launched PYRA, a multi-agent coordination system with a Credit System and reputation-based distribution model, in March 2026, and additional Developer Analytic Tools automate insight extraction from session replays. Leadership comprises CEO Asaf Zviran, Chief Science Officer Orly Alter, and CTO Daniel Shabtai. Business model mechanics are not publicly disclosed: pricing is not published, no revenue figure is available, no paying customers are named, and the only funding entry records $0 from Evolution VC Partners and Vela Partners in early 2025.

Prism AI firmographics

Firmographics
Name
Prism AI
Legal name
PRISM AI PTE. LTD.
Website
https://prism-ai.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Prism AI is a University of Utah spinoff applying a proprietary quantum mechanics-based AI technique to genomic and molecular data, enabling biotech and pharma customers to optimize clinical trial design, identify drug targets, and predict cancer outcomes from small patient cohorts.
Ownership category
akta.pro rank

Prism AI industry classification

Industry
Product category
AI Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHDAEANAA
End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise
SECONDARYBPAEAHAK
Industry/Domain Analytics Solutions & Accelerators

Keywords

  • AI drug discovery
  • Biomarker analysis
  • Multi-agent systems
  • Quantum AI
  • Molecular profiling

Where Prism AI is headquartered

Location

Headquarters

HQ city
Salt Lake City
HQ country
United States
HQ region
North America

Markets served

Prism AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel

Prism AI product offering

Product offering

Core offering

Prism AI develops quantum mechanics-based AI/ML algorithms that analyze millions to billions of molecular features from small patient cohorts (20-100 people) to predict cancer treatment outcomes and identify optimal drug targets. The company offers Prism AI Therapeutics for biotech and pharma clinical trial optimization, PYRA—a multi-agent system that coordinates AI agents through a unified execution network—and developer analytic tools that automate insight extraction from session replays.

Product overview

Prism AI operates as a multi-product technology company with distinct offerings across different domains. The portfolio includes Prism AI Therapeutics (a healthcare/biotech spinoff using quantum AI for cancer research), PYRA (a multi-agent coordination system for AI execution), and Developer Analytic Tools (session replay analytics for product teams). These products address different market segments including biotech/pharmaceutical research, AI agent orchestration, and developer productivity tools.

Differentiator

Problem solved

Functional benefit

Brands

  • PYRA: A multi-agent system designed to coordinate AI agents through a unified execution network where users submit objectives and the platform routes tasks across multiple agents to produce combined outputs. Includes an economic layer featuring a Credit System and reputation-based distribution model.

Products and services

  • Prism AI Therapeutics A University of Utah spinoff commercializing quantum AI algorithms for biotech and pharmaceutical companies to identify optimal patient subgroups and drug targets for clinical trials, validated through CRISPR-Cas9 gene editing.
  • PYRA A multi-agent system designed to coordinate AI agents through a unified execution network where users submit objectives and the platform routes tasks across multiple agents to produce combined outputs, featuring an economic layer with a Credit System and reputation-based distribution model.
  • Developer Analytic Tools

Quantifiable outcome

  • Discovered two new predictors of neuroblastoma patient life expectancy that consistently outperform standard biomarkers
  • +2 more outcomes

Companies that use Prism AI

Customer profile

Segments1 record

Ideal customer profiles2 records

Prism AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature3 records

Prism AI partnerships and signals

Strategic signal

Recent moves8 records

Expansion highlights4 records

Prism AI competitors and assessment

Company assessment

Direct peers

  • Owkin: AI for clinical and translational research using patient-level data to discover biomarkers and predict treatment outcomes — the closest peer to Prism's biomarker and subgroup discovery from patient cohort data.
  • Insitro: Machine-learning-enabled drug discovery company combining wet-lab biology with predictive models to identify targets and patient subgroups — closely aligned with Prism's small-cohort, biology-grounded AI approach.
  • BenevolentAI: AI platform for drug discovery and biomarker identification using biomedical knowledge graphs and ML — comparable AI-for-discovery and target-identification value proposition.
  • GNS Healthcare: Causal AI platform for patient-level outcome prediction and biomarker discovery from real-world and clinical data — closely aligned with Prism's predictive modeling from small patient cohorts.
  • PathAI: AI platform for pathology-based biomarker discovery and diagnostic development — comparable on AI-driven biomarker identification supporting pharma clinical programs.
  • Exscientia: AI-driven precision medicine and drug discovery company using machine learning to design therapeutics and stratify patients — comparable end-to-end platform positioning to Prism AI Therapeutics.
  • Schrödinger: Physics-based and AI-driven molecular simulation platform for drug discovery and materials — comparable on computationally intensive molecular modeling feeding pharma R&D workflows.
  • Recursion Pharmaceuticals: AI-driven drug discovery platform using high-throughput biology and machine learning to identify therapeutics — directly comparable to Prism AI Therapeutics on AI-for-drug-development positioning.

Broad incumbents

  • ConcertAI: AI solutions for clinical and real-world evidence analytics serving pharma R&D and commercialization — overlapping incumbent serving the same biotech/pharma buyer with adjacent analytics offerings.
  • Tempus Labs: Large AI-enabled precision medicine company aggregating clinical and molecular data for oncology — broader incumbent that overlaps with Prism's biomarker and patient-stratification use cases for pharma/biotech customers.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Prism AI social profiles

Digital presence

Prism AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prism AI leadership team

Management profile

Number of profiles

Profiles3 records

Prism AI funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prism AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prism AI

What does Prism AI do?

Prism AI develops quantum mechanics-based AI/ML algorithms that analyze millions to billions of molecular features from small patient cohorts (20-100 people) to predict cancer treatment outcomes and identify optimal drug targets. The company offers Prism AI Therapeutics for biotech and pharma clinical trial optimization, PYRA—a multi-agent system that coordinates AI agents through a unified execution network—and developer analytic tools that automate insight extraction from session replays.

Is Prism AI a public or private company?

Prism AI is a private company. It is classified as venture growth investor backed and is currently operating.

When was Prism AI founded?

Prism AI was founded in 2024. It employs 1 to 10 people.

Where is Prism AI based?

Prism AI is headquartered in Salt Lake City, United States, in the North America region.

Who are Prism AI's main competitors?

Direct peers on record are Owkin, Insitro, BenevolentAI, GNS Healthcare, PathAI, Exscientia, Schrödinger and Recursion Pharmaceuticals. Broad incumbents are ConcertAI and Tempus Labs.

Does Prism AI have an API?

No public API is recorded for Prism AI.

What industry is Prism AI in?

Prism AI's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mirage NewsQuantum AI Breakthroughs Boost Cancer OutcomesResearchers at the University of Utah's Scientific Computing & Imaging Institute developed a novel quantum mechanics-based AI/ML technique that can analyze millions to billions of molecular features from small patient cohorts to predict cancer treatment outcomes, addressing a key limitation of conventional AI approaches that require vastly more patient samples than genetic features. The technique, published in APL Quantum, was demonstrated on neuroblastoma data where it discovered two new predictors of patient life expectancy that consistently outperformed standard biomarkers across tumor and blood DNA and tumor RNA. The researchers' university spinoff company, Prism AI Therapeutics, is already using the algorithms to help biotech and pharmaceutical companies identify optimal patient subgroups and drug targets for clinical trials.Mirage NewsQuantum Mechanics Boosts AI for Better Cancer OutcomesResearchers at the University of Utah developed a novel AI/ML technique based on quantum mechanics concepts that can better predict cancer patient outcomes, addressing a key limitation of conventional AI approaches that require vastly more patient samples than available in typical clinical trials of 20-100 people. The technique, published in Applied Physics Letters (APL) Quantum, uses multitensor comparative spectral decompositions to analyze millions to billions of molecular features from patients and demonstrated two new predictors of neuroblastoma patient life expectancy that outperformed standard biomarkers. The research team, led by associate professor Orly Alter, has formed a university spinoff company called Prism AI Therapeutics to commercialize the algorithms for biotech and pharmaceutical drug development.TrendHunter.comDeveloper Analytic ToolsPrism AI is a developer tooling product that automates insight extraction from session replays, identifying issues and recommending fixes from user behavior data without manual event tagging. The article positions this within broader trends of passive analytics systems designed to reduce setup complexity while increasing signal clarity for product teams. It explores industry implications for software development tools, product analytics platforms, and customer experience suites.EIN PresswirePRISM AI Announces Launch of PYRA Multi-Agent System Desktop Version for Coordinated AI Agent ExecutionPRISM AI PTE. LTD. announced the launch of the desktop version of PYRA, a multi-agent system designed to coordinate AI agents through a unified execution network where users submit objectives and the platform routes tasks across multiple agents to produce combined outputs. The platform includes an economic layer featuring a Credit System and reputation-based distribution model intended to incentivize both users and creators participating in the network. The company stated the desktop launch represents an initial stage in the PYRA roadmap, with future updates expected to introduce additional features and capabilities.